Press Release

PharmAla Biotech to supply University of California Clinical Trial with LaNeo™ MDMA

PharmAla Biotech, the first public company to manufacture GMP MDMA, is now a vendor to the University of California system

VANCOUVER, BC, Oct. 4, 2022 /CNW/ - PharmAla Biotech is gratified to have been selected as the MDMA manufacturing partner for a human MDMA trial at a campus of the University of California. The University of California system encompasses 10 campuses across the State of California; This is the first US-based Clinical Trial to utilize PharmAla's LaNeo™ MDMA.

"The UC System is the location for some of the most exciting Psychedelics research going on anywhere on the planet. PharmAla is proud to not only be a UC vendor, but to continue to expand our presence in supplying some of the best researchers in the United States," said Nick Kadysh, PharmAla's CEO. "Anywhere MDMA research is happening, PharmAla is now the preeminent vendor for clinical trial materials."

The University of California has requested that PharmAla maintain confidentiality regarding both the Campus and Principal Investigator of the trial in order to allow for unbiased patient recruitment.

PharmAla's LaNeo MDMA will be delivered to the University of California in one tranche, with deliveries beginning in early 2023. The total contract value is approximately $65,000 US.

About PharmAla

PharmAla Biotech Holdings Inc. (CSE: MDMA) is a biotechnology company focused on the research, development, and manufacturing of MDXX class molecules, including MDMA. PharmAla was founded with a dual focus: alleviating the global backlog of generic, clinical-grade MDMA to enable clinical trials, and to develop novel drugs in the same class. PharmAla is a “regulatory first” organization, formed under the principle that true success in the psychedelics industry will only be achieved through excellent relationships with regulators. Our team of dedicated professionals includes regulatory experts, scientists, and biomanufacturing professionals. PharmAla has built what it believes to be North America’s first cGMP MDMA value chain, encompassing GMP manufacturing of Active Pharmaceutical Ingredient (API), and drug product formulation. PharmAla’s research and development unit has also begun preclinical research into two patented Novel Chemical Entities (NCEs) based on MDXX class molecules, with proof-of-concept research currently ongoing at the University of Arkansas Medical School.

Media Inquiries

Nicholas Kadysh, CEO